Results 41 to 50 of about 936,037 (347)
NAFLD‐related hepatocellular carcinoma: The growing challenge
Hepatology, EarlyView., 2022 Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah +2 more
wiley +1 more source
Drug-related problems and dosage adjustment in patients with liver disease [PDF]
, 2012 The liver is essential for the metabolism of medicinal substances. Liver disease, especially liver cirrhosis, may lead to various pharmacokinetic and pharmacodynamic changes, predisposing patients with liver cirrhosis to adverse drug events (ADEs).
Franz, Carmen Carina
core +1 more source
Hepatology, EarlyView., 2022 Graphical summary of obesity‐induced NASH progression by LCN2 targeted to HSC activation. Abstract Background and Aims In obesity and type 2 diabetes mellitus, leptin promotes insulin resistance and contributes to the progression of NASH via activation of hepatic stellate cells (HSCs).
Kyung Eun Kim +12 more
wiley +1 more source
Contemporary management of pain in cirrhosis: Toward precision therapy for pain
Hepatology, EarlyView., 2022 Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman +4 more
wiley +1 more source
Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis [PDF]
, 1991 In 11 patients with decompensated cirrhosis and deteriorating renal function, the effect of the vasoconstrictor substance 8-ornithin vasopressin (ornipressin; POR 8; Sandoz, Basel, Switzerland) on renal function, hemodynamic parameters, and humoral ...
Reither, H. +8 more
core +1 more source
Hepatite vírica crónica: proposta de um protocolo para o tratamento/seguimento da cirrose.
Acta Médica Portuguesa, 2008 Cirrhosis is the terminal phase of hepatic fibrosis, that leads to impaired hepatic function and blood flow. Liver cirrhosis is the final stage of many hepatic diseases characterized by chronic cellular destruction.
Vicens Diaz-Brito +2 more
doaj +1 more source
Hepatology, EarlyView., 2022 IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu +20 more
wiley +1 more source
Dose adaptation of drugs in patients with liver disease [PDF]
, 2004 In my thesis I defined strategies for dosage adaptation of drugs in patients with liver disease. The major goal of the thesis was to classify antineoplastic drugs and central nervous agents according to pharmacokinetic principles (hepatic extraction and ...
Tchambaz, Lydia
core +1 more source
Vaccines, 2022 Patients with cirrhosis are vulnerable to hepatic decompensation events and death following COVID-19 infection. Therefore, primary vaccination with COVID-19 vaccines is fundamental to reducing the risk of COVID-19 related deaths in patients with ...
Bálint Drácz +7 more
doaj +1 more source
Clinical Features of Hepatic Cirrhosis in Hypopituitarism [PDF]
Zhongguo quanke yixue, 2023 Background Hepatic cirrhosis represents the final stage for a wide variety of chronic liver diseases, which may be induced by numerous causes, and is associated with high mortality when complications arise.
SHI Xuexiu, YUN Wenjing, WANG Haixu, ZHAO Yingying, YANG Yanan, SUN Tongwen
doaj +1 more source